Uses of polypills for cardiovascular disease and evidence to date

Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for the use of polypills in fu...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 389; no. 10073; pp. 1055 - 1065
Main Authors:	Huffman, Mark D, Xavier, Denis, Perel, Pablo
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 11.03.2017 Elsevier Limited
Subjects:	Atherosclerosis Cardiovascular disease Cardiovascular diseases Disease prevention Drug dosages Drug therapy Health risk assessment Heterogeneity Internal Medicine Lipids Malaria Pharmaceutical industry Prevention Purchasing contracts Risk assessment Risk factors Studies Tuberculosis Vector-borne diseases
ISSN:	0140-6736, 1474-547X, 1474-547X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for the use of polypills in future research and clinical activities and to synthesise contemporary evidence supporting the use of polypills for prevention of atherosclerosis. Polypill uses can be categorised by population and indication, both of which influence the balance between benefits and risks. Populations include secondary prevention, high-risk primary prevention based on formal risk assessment, and primary prevention based on single risk factor measurement, such as age, also known as mass treatment. For each population, potential indications are initiation, step-up of current drug therapy, and straight substitution of individual drug components. We summarise efficacy and safety results from 13 polypill trials (9059 participants) done in 32 countries. Polypills improve adherence, are generally well tolerated, and reduce risk factor levels, although heterogeneity limits the certainty of the effect on risk factors. Trials published to date have not been designed to detect differences in clinical outcomes, and thus no significant differences between polypill and comparator groups have been reported. Polypill therapy could be one of the most scalable strategies to reduce the risk of premature mortality from atherosclerosis by 25% by 2025 by improving medication adherence and access, but further trial data and clinical experience will be useful to determine how polypills can best be implemented to achieve this goal.
AbstractList	Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for the use of polypills in future research and clinical activities and to synthesise contemporary evidence supporting the use of polypills for prevention of atherosclerosis. Polypill uses can be categorised by population and indication, both of which influence the balance between benefits and risks. Populations include secondary prevention, high-risk primary prevention based on formal risk assessment, and primary prevention based on single risk factor measurement, such as age, also known as mass treatment. For each population, potential indications are initiation, step-up of current drug therapy, and straight substitution of individual drug components. We summarise efficacy and safety results from 13 polypill trials (9059 participants) done in 32 countries. Polypills improve adherence, are generally well tolerated, and reduce risk factor levels, although heterogeneity limits the certainty of the effect on risk factors. Trials published to date have not been designed to detect differences in clinical outcomes, and thus no significant differences between polypill and comparator groups have been reported. Polypill therapy could be one of the most scalable strategies to reduce the risk of premature mortality from atherosclerosis by 25% by 2025 by improving medication adherence and access, but further trial data and clinical experience will be useful to determine how polypills can best be implemented to achieve this goal. Summary Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for the use of polypills in future research and clinical activities and to synthesise contemporary evidence supporting the use of polypills for prevention of atherosclerosis. Polypill uses can be categorised by population and indication, both of which influence the balance between benefits and risks. Populations include secondary prevention, high-risk primary prevention based on formal risk assessment, and primary prevention based on single risk factor measurement, such as age, also known as mass treatment. For each population, potential indications are initiation, step-up of current drug therapy, and straight substitution of individual drug components. We summarise efficacy and safety results from 13 polypill trials (9059 participants) done in 32 countries. Polypills improve adherence, are generally well tolerated, and reduce risk factor levels, although heterogeneity limits the certainty of the effect on risk factors. Trials published to date have not been designed to detect differences in clinical outcomes, and thus no significant differences between polypill and comparator groups have been reported. Polypill therapy could be one of the most scalable strategies to reduce the risk of premature mortality from atherosclerosis by 25% by 2025 by improving medication adherence and access, but further trial data and clinical experience will be useful to determine how polypills can best be implemented to achieve this goal. Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for the use of polypills in future research and clinical activities and to synthesise contemporary evidence supporting the use of polypills for prevention of atherosclerosis. Polypill uses can be categorised by population and indication, both of which influence the balance between benefits and risks. Populations include secondary prevention, high-risk primary prevention based on formal risk assessment, and primary prevention based on single risk factor measurement, such as age, also known as mass treatment. For each population, potential indications are initiation, step-up of current drug therapy, and straight substitution of individual drug components. We summarise efficacy and safety results from 13 polypill trials (9059 participants) done in 32 countries. Polypills improve adherence, are generally well tolerated, and reduce risk factor levels, although heterogeneity limits the certainty of the effect on risk factors. Trials published to date have not been designed to detect differences in clinical outcomes, and thus no significant differences between polypill and comparator groups have been reported. Polypill therapy could be one of the most scalable strategies to reduce the risk of premature mortality from atherosclerosis by 25% by 2025 by improving medication adherence and access, but further trial data and clinical experience will be useful to determine how polypills can best be implemented to achieve this goal.Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for the use of polypills in future research and clinical activities and to synthesise contemporary evidence supporting the use of polypills for prevention of atherosclerosis. Polypill uses can be categorised by population and indication, both of which influence the balance between benefits and risks. Populations include secondary prevention, high-risk primary prevention based on formal risk assessment, and primary prevention based on single risk factor measurement, such as age, also known as mass treatment. For each population, potential indications are initiation, step-up of current drug therapy, and straight substitution of individual drug components. We summarise efficacy and safety results from 13 polypill trials (9059 participants) done in 32 countries. Polypills improve adherence, are generally well tolerated, and reduce risk factor levels, although heterogeneity limits the certainty of the effect on risk factors. Trials published to date have not been designed to detect differences in clinical outcomes, and thus no significant differences between polypill and comparator groups have been reported. Polypill therapy could be one of the most scalable strategies to reduce the risk of premature mortality from atherosclerosis by 25% by 2025 by improving medication adherence and access, but further trial data and clinical experience will be useful to determine how polypills can best be implemented to achieve this goal.
Author	Huffman, Mark D Xavier, Denis Perel, Pablo
Author_xml	– sequence: 1 givenname: Mark D surname: Huffman fullname: Huffman, Mark D email: m-huffman@northwestern.edu organization: Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA – sequence: 2 givenname: Denis surname: Xavier fullname: Xavier, Denis organization: Department of Pharmacology and Division of Clinical Research, St John's Medical College and Research Institute, St John's National Academy of Health Sciences, Bangalore, India – sequence: 3 givenname: Pablo surname: Perel fullname: Perel, Pablo organization: Centre for Global Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28290995$$D View this record in MEDLINE/PubMed
BookMark	eNqNkV1rFDEUhoNU7Lb6E5QBb-rFaJLJxwxSpZRWhYIXWvAunE1OIDU7WZOZhf33zuy2CgtSr3LzvE8O73tCjvrUIyEvGX3LKFPvvlEmaK10o86YftNQKZtaPSELJrSopdA_jsjiD3JMTkq5o5QKReUzcsxb3tGukwtycVuwVMlX6xS36xBjqXzKlYXsQtpAsWOEXLlQEApW0LsKN8Fhb7EaUuVgwOfkqYdY8MX9e0pur6--X36ub75--nJ5cVNbSflQt0pKlEvmuQLpdNtZL5wGvaSqRU65dFII6i0soWG29UJ6JUWngHEHykNzSs723nVOv0Ysg1mFYjFG6DGNxbBWa8m1Us2Evj5A79KY--m6mVJCU8rFRL26p8blCp1Z57CCvDUP5UzA-z1gcyolozc2DDCE1A8ZQjSMmnkKs5vCzD0bps1uCqOmtDxIP3zwWO7jPodTmZuA2RQb5sJdyGgH41J41PDhwGBj6IOF-BO3WP52YQo3dC-ZHUzvDLPg_N-C_zjgNy_Xxow
CODEN	LANCAO
CitedBy_id	crossref_primary_10_1097_HJH_0000000000001581 crossref_primary_10_2459_JCM_0000000000001159 crossref_primary_10_1016_j_jclinepi_2018_10_014 crossref_primary_10_1161_CIRCULATIONAHA_119_041297 crossref_primary_10_1016_j_artere_2018_04_004 crossref_primary_10_1136_dtb_2017_6_0486 crossref_primary_10_3390_pharmaceutics12090795 crossref_primary_10_1159_000511064 crossref_primary_10_1007_s10654_024_01138_0 crossref_primary_10_1056_NEJMe2210020 crossref_primary_10_1136_heartjnl_2023_323614 crossref_primary_10_1136_bmjopen_2018_021479 crossref_primary_10_1016_j_jconrel_2018_05_024 crossref_primary_10_1111_jch_14866 crossref_primary_10_1177_09691413241235488 crossref_primary_10_1177_2047487317707324 crossref_primary_10_1097_HJH_0000000000001390 crossref_primary_10_3390_jcm12237226 crossref_primary_10_1080_14737167_2020_1734456 crossref_primary_10_1177_1747493018761190 crossref_primary_10_3390_pharmaceutics15112636 crossref_primary_10_1016_j_eurpolymj_2024_113245 crossref_primary_10_1097_HJH_0000000000002464 crossref_primary_10_1016_j_jacc_2025_04_043 crossref_primary_10_1097_HJH_0000000000002108 crossref_primary_10_1016_j_jacc_2019_04_067 crossref_primary_10_1016_j_nrleng_2017_10_008 crossref_primary_10_1038_s41598_021_84455_8 crossref_primary_10_1136_heartjnl_2018_313492 crossref_primary_10_1136_bmjopen_2018_025587 crossref_primary_10_1016_S0140_6736_17_30558_5 crossref_primary_10_1111_jch_13162 crossref_primary_10_1111_sdi_12925 crossref_primary_10_1038_s41579_018_0141_x crossref_primary_10_1038_s41591_024_02896_w crossref_primary_10_1097_HJH_0000000000002072 crossref_primary_10_3390_pharmaceutics10040203 crossref_primary_10_1007_s11886_024_02046_1 crossref_primary_10_1016_j_pharmthera_2020_107698 crossref_primary_10_1016_j_jash_2018_02_008 crossref_primary_10_1186_s12872_020_01370_y crossref_primary_10_1371_journal_pmed_1003590 crossref_primary_10_1016_j_bja_2021_05_006 crossref_primary_10_1016_j_arcmed_2019_04_001 crossref_primary_10_1161_JAHA_123_032236 crossref_primary_10_1007_s00228_022_03314_1 crossref_primary_10_1097_QAD_0000000000001677 crossref_primary_10_1016_j_matbio_2018_03_003 crossref_primary_10_1016_j_ijpharm_2024_125013 crossref_primary_10_1111_bjhp_12332 crossref_primary_10_1186_s13031_019_0217_x crossref_primary_10_36290_vnl_2017_141 crossref_primary_10_1007_s10741_025_10559_2 crossref_primary_10_1177_1753944718764588 crossref_primary_10_1038_s41390_019_0630_2 crossref_primary_10_1080_14656566_2018_1532501 crossref_primary_10_1038_s41598_020_60799_5 crossref_primary_10_1161_JAHA_119_015491 crossref_primary_10_1093_eurheartj_ehac515 crossref_primary_10_1136_dtb_2019_000027 crossref_primary_10_1016_j_rec_2019_11_008 crossref_primary_10_1371_journal_pone_0182625 crossref_primary_10_1161_STROKEAHA_122_037313 crossref_primary_10_1016_S0140_6736_19_31791_X crossref_primary_10_1016_j_cpcardiol_2021_100872 crossref_primary_10_1016_j_compchemeng_2021_107492 crossref_primary_10_4103_npmj_npmj_256_22 crossref_primary_10_1177_20451253211000610 crossref_primary_10_1016_S0140_6736_19_31953_1 crossref_primary_10_1016_j_gheart_2018_10_001 crossref_primary_10_1136_bmjopen_2022_063668 crossref_primary_10_1007_s11906_021_01159_0 crossref_primary_10_1016_j_amepre_2022_03_027 crossref_primary_10_1016_S0140_6736_17_31468_X
Cites_doi	10.1016/j.recesp.2016.05.011 10.1161/CIRCOUTCOMES.115.001483 10.5694/mja14.00266 10.1001/jama.2013.277064 10.1001/jamacardio.2016.0218 10.1002/14651858.CD009868.pub2 10.1056/NEJMoa1600175 10.1016/j.jacc.2013.08.1665 10.1185/03007995.2011.555754 10.1177/2047487313476961 10.1186/1745-6215-12-3 10.1177/2047487316638501 10.1161/CIRCOUTCOMES.113.000189 10.1161/CIR.0000000000000467 10.1016/j.ijcard.2015.12.015 10.1136/heartjnl-2014-305693 10.1136/bmj.326.7404.1419 10.1111/j.1751-7176.2008.00058.x 10.1136/bmj.g3318 10.1177/2047487316637196 10.1016/S0140-6736(14)62070-5 10.1371/journal.pmed.1001862 10.1016/j.jacc.2013.09.053 10.1016/S0140-6736(11)61215-4 10.1016/S0140-6736(17)30558-5 10.1136/bmj.39489.470347.AD 10.1161/JAHA.114.001709 10.1186/s13012-016-0488-1 10.7326/M16-0577 10.1093/eurheartj/eht407 10.1016/j.jacc.2014.08.021 10.1161/CIRCOUTCOMES.113.000112 10.2147/DDDT.S112873 10.1136/bmjopen-2014-007111 10.1177/1060028015570468 10.1258/jrsm.2009.090293 10.1016/S0140-6736(09)60611-5 10.1177/2047487314550803 10.2147/VHRM.S7710 10.1371/journal.pone.0019857 10.1136/bmj.329.7480.1447 10.1161/CIRCOUTCOMES.111.000058 10.1111/1755-5922.12151 10.1177/2047487314530382 10.1016/S0140-6736(17)30260-X 10.1016/j.amjmed.2006.08.033 10.1002/14651858.CD009868.pub3 10.1186/s12967-016-0997-3 10.1371/journal.pone.0041297 10.1161/CIRCOUTCOMES.111.963637 10.1111/j.1742-1241.2010.02412.x
ContentType	Journal Article
Copyright	2017 Elsevier Ltd Elsevier Ltd Copyright © 2017 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Mar 11, 2017
Copyright_xml	– notice: 2017 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2017 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Mar 11, 2017
DBID	AAYXX CITATION NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PSYQQ Q9U S0X 7X8
DOI	10.1016/S0140-6736(17)30553-6
DatabaseName	CrossRef PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database (ProQuest) Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Collection (ProQuest) British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database (ProQuest) Medical Database Psychology Database Research Library (ProQuest) Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic
DatabaseTitle	CrossRef PubMed ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	PubMed ProQuest One Psychology MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1474-547X
EndPage	1065
ExternalDocumentID	4320344441 28290995 10_1016_S0140_6736_17_30553_6 S0140673617305536 1_s2_0_S0140673617305536
Genre	Journal Article Review
GroupedDBID	--- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHHHB AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L M41 MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU UQL WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 9DU AAYXX ADXHL AFFHD AGQPQ AIGII CITATION AGCQF AGRNS NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI Q9U 7X8
ID	FETCH-LOGICAL-c502t-8655e5b1f26a5d789cf4d7a7b068e2025d5440fcaba31c8f45f65496a12da6fa3
IEDL.DBID	7RV
ISICitedReferencesCount	89
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000396345200027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0140-6736 1474-547X
IngestDate	Sun Nov 09 12:56:43 EST 2025 Sat Nov 29 14:56:12 EST 2025 Mon Jul 21 06:05:16 EDT 2025 Sat Nov 29 05:12:54 EST 2025 Tue Nov 18 22:25:23 EST 2025 Fri Feb 23 02:32:32 EST 2024 Sun Feb 23 10:19:29 EST 2025 Tue Oct 14 19:40:25 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	10073
Language	English
License	Copyright © 2017 Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c502t-8655e5b1f26a5d789cf4d7a7b068e2025d5440fcaba31c8f45f65496a12da6fa3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
PMID	28290995
PQID	1876470024
PQPubID	40246
PageCount	11
ParticipantIDs	proquest_miscellaneous_1877527663 proquest_journals_1876470024 pubmed_primary_28290995 crossref_citationtrail_10_1016_S0140_6736_17_30553_6 crossref_primary_10_1016_S0140_6736_17_30553_6 elsevier_sciencedirect_doi_10_1016_S0140_6736_17_30553_6 elsevier_clinicalkeyesjournals_1_s2_0_S0140673617305536 elsevier_clinicalkey_doi_10_1016_S0140_6736_17_30553_6
PublicationCentury	2000
PublicationDate	2017-03-11
PublicationDateYYYYMMDD	2017-03-11
PublicationDate_xml	– month: 03 year: 2017 text: 2017-03-11 day: 11
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London
PublicationTitle	The Lancet (British edition)
PublicationTitleAlternate	Lancet
PublicationYear	2017
Publisher	Elsevier Ltd Elsevier Limited
Publisher_xml	– name: Elsevier Ltd – name: Elsevier Limited
References	Patel, Cass, Peiris (bib18) 2015; 22 Grimm, Malik, Yunis, Sutradhar, Kursun (bib27) 2010; 6 Barrios, Kaskens, Castellano (bib54) 2016; 70 Castellano, Sanz, Peñalvo (bib20) 2014; 64 Thom, Poulter, Field (bib16) 2013; 310 Goff, Lloyd-Jones, Bennett (bib37) 2013; 129 Huffman, Prabhakaran, Abraham (bib36) 2013; 6 Becerra, Gracia, Desai (bib53) 2015; 5 (bib2) 2013 Truelove, Patel, Bompoint (bib56) 2015; 33 Hawkins, Scholes, Bajekal (bib33) 2013; 6 (bib1) 2002 Bangalore, Kamalakkannan, Parkar, Messerli (bib5) 2007; 120 Yusuf, Pais, Sigamani (bib19) 2012; 5 Soliman, Mendis, Dissanayake (bib25) 2011; 12 Bibbins-Domingo (bib44) 2016; 164 Zamorano, Erdine, Pavia (bib15) 2011; 27 Huffman, Yusuf (bib8) 2014; 63 Wald, Morris, Wald (bib28) 2012; 7 Laba, Hayes, Lo (bib55) 2014; 201 Karmali, Lloyd-Jones, Berendsen (bib42) 2016; 1 Chow, Thakkar, Bennett (bib50) 2017 Smith (bib46) 2009; 102 Selak, Harwood, Raina Elley (bib52) 2016; 23 Lloyd-Jones, Huffman, Karmali (bib43) 2016 Lafeber, Grobbee, Bots (bib49) 2014; 21 Sundström, Arima, Woodward (bib40) 2014; 384 Shah, Huffman, Ning, Lloyd-Jones (bib30) 2015; 4 Shah, Huffman, Ning, Lloyd-Jones (bib31) 2013; 6 (bib9) 2014; 35 Webster, Castellano, Onuma (bib13) 2017; 389 Franco, Bonneux, de Laet, Peeters, Steyerberg, Mackenbach (bib45) 2004; 329 Liu, Massi, Laba (bib58) 2015; 8 (bib4) 2015 Beall, Schwalm, Huffman, McCready, Yusuf, Attaran (bib10) 2016; 14 Laba, Howard, Rose (bib57) 2015; 49 Hayek, Joshi, Usherwood (bib34) 2016; 11 Bahiru, de Cates, Farr (bib48) 2017 Malekzadeh, Marshall, Pourshams (bib22) 2010; 64 Yusuf, Pais, Afzal (bib26) 2009; 373 Yusuf, Islam, Chow (bib29) 2011; 378 Santo, Kirkendall, Laba (bib7) 2016; 23 Huffman (bib6) 2015; 12 Maddox, Chan, Spertus (bib32) 2014; 63 de Cates, Farr, Wright (bib12) 2014; 4 Boon, Boyle, Bradbury, Buckley, Connolly (bib38) 2014; 100 Lonn, Bosch, Lopez-Jaramillo (bib39) 2016; 374 Ostovaneh, Poustchi, Hemming (bib41) 2015; 22 Rodgers, Patel (bib24) 2011; 6 Selak, Elley, Bullen (bib17) 2014; 348 Wald, Law (bib14) 2003; 326 Park, Shin, Hong (bib23) 2016; 10 Guyatt, Oxman, Vist (bib35) 2008; 336 (bib11) 2017 (bib3) 2016 Heart Outcomes and Prevention Evaluation. (accessed Feb 13, 2017). Neutel, Bestermann, Dyess (bib21) 2009; 11 Webster, Patel, Selak (bib51) 2016; 205 (10.1016/S0140-6736(17)30553-6_bib3) 2016 Selak (10.1016/S0140-6736(17)30553-6_bib52) 2016; 23 Hawkins (10.1016/S0140-6736(17)30553-6_bib33) 2013; 6 Ostovaneh (10.1016/S0140-6736(17)30553-6_bib41) 2015; 22 Webster (10.1016/S0140-6736(17)30553-6_bib51) 2016; 205 Webster (10.1016/S0140-6736(17)30553-6_bib13) 2017; 389 Liu (10.1016/S0140-6736(17)30553-6_bib58) 2015; 8 Shah (10.1016/S0140-6736(17)30553-6_bib31) 2013; 6 Grimm (10.1016/S0140-6736(17)30553-6_bib27) 2010; 6 Rodgers (10.1016/S0140-6736(17)30553-6_bib24) 2011; 6 10.1016/S0140-6736(17)30553-6_bib47 Lafeber (10.1016/S0140-6736(17)30553-6_bib49) 2014; 21 Yusuf (10.1016/S0140-6736(17)30553-6_bib19) 2012; 5 Lonn (10.1016/S0140-6736(17)30553-6_bib39) 2016; 374 de Cates (10.1016/S0140-6736(17)30553-6_bib12) 2014; 4 Truelove (10.1016/S0140-6736(17)30553-6_bib56) 2015; 33 Bahiru (10.1016/S0140-6736(17)30553-6_bib48) 2017 (10.1016/S0140-6736(17)30553-6_bib2) 2013 Boon (10.1016/S0140-6736(17)30553-6_bib38) 2014; 100 Laba (10.1016/S0140-6736(17)30553-6_bib57) 2015; 49 Santo (10.1016/S0140-6736(17)30553-6_bib7) 2016; 23 Bangalore (10.1016/S0140-6736(17)30553-6_bib5) 2007; 120 Hayek (10.1016/S0140-6736(17)30553-6_bib34) 2016; 11 Huffman (10.1016/S0140-6736(17)30553-6_bib36) 2013; 6 Goff (10.1016/S0140-6736(17)30553-6_bib37) 2013; 129 Lloyd-Jones (10.1016/S0140-6736(17)30553-6_bib43) 2016 Yusuf (10.1016/S0140-6736(17)30553-6_bib26) 2009; 373 Patel (10.1016/S0140-6736(17)30553-6_bib18) 2015; 22 Wald (10.1016/S0140-6736(17)30553-6_bib14) 2003; 326 Maddox (10.1016/S0140-6736(17)30553-6_bib32) 2014; 63 Huffman (10.1016/S0140-6736(17)30553-6_bib8) 2014; 63 Franco (10.1016/S0140-6736(17)30553-6_bib45) 2004; 329 Neutel (10.1016/S0140-6736(17)30553-6_bib21) 2009; 11 Wald (10.1016/S0140-6736(17)30553-6_bib28) 2012; 7 Thom (10.1016/S0140-6736(17)30553-6_bib16) 2013; 310 Sundström (10.1016/S0140-6736(17)30553-6_bib40) 2014; 384 Smith (10.1016/S0140-6736(17)30553-6_bib46) 2009; 102 Barrios (10.1016/S0140-6736(17)30553-6_bib54) 2016; 70 Castellano (10.1016/S0140-6736(17)30553-6_bib20) 2014; 64 Chow (10.1016/S0140-6736(17)30553-6_bib50) 2017 Huffman (10.1016/S0140-6736(17)30553-6_bib6) 2015; 12 Zamorano (10.1016/S0140-6736(17)30553-6_bib15) 2011; 27 Bibbins-Domingo (10.1016/S0140-6736(17)30553-6_bib44) 2016; 164 Karmali (10.1016/S0140-6736(17)30553-6_bib42) 2016; 1 (10.1016/S0140-6736(17)30553-6_bib4) 2015 (10.1016/S0140-6736(17)30553-6_bib1) 2002 Park (10.1016/S0140-6736(17)30553-6_bib23) 2016; 10 Guyatt (10.1016/S0140-6736(17)30553-6_bib35) 2008; 336 Beall (10.1016/S0140-6736(17)30553-6_bib10) 2016; 14 Shah (10.1016/S0140-6736(17)30553-6_bib30) 2015; 4 Selak (10.1016/S0140-6736(17)30553-6_bib17) 2014; 348 (10.1016/S0140-6736(17)30553-6_bib9) 2014; 35 Becerra (10.1016/S0140-6736(17)30553-6_bib53) 2015; 5 Malekzadeh (10.1016/S0140-6736(17)30553-6_bib22) 2010; 64 Soliman (10.1016/S0140-6736(17)30553-6_bib25) 2011; 12 Yusuf (10.1016/S0140-6736(17)30553-6_bib29) 2011; 378 Laba (10.1016/S0140-6736(17)30553-6_bib55) 2014; 201 28290999 - Lancet. 2017 Mar 11;389(10073):984
References_xml	– volume: 205 start-page: 147 year: 2016 end-page: 156 ident: bib51 article-title: Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries publication-title: Int J Cardiol – volume: 14 start-page: 242 year: 2016 ident: bib10 article-title: Could patents interfere with the development of a cardiovascular polypill? publication-title: J Transl Med – volume: 374 start-page: 2009 year: 2016 end-page: 2020 ident: bib39 article-title: Blood-pressure lowering in intermediate-risk persons without cardiovascular disease publication-title: N Engl J Med – volume: 64 start-page: 2071 year: 2014 end-page: 2082 ident: bib20 article-title: A polypill strategy to improve adherence: results from the FOCUS project publication-title: J Am Coll Cardiol – volume: 1 start-page: 341 year: 2016 end-page: 349 ident: bib42 article-title: Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews publication-title: JAMA Cardiol – volume: 373 start-page: 1341 year: 2009 end-page: 1351 ident: bib26 article-title: Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial publication-title: Lancet – year: 2017 ident: bib48 article-title: Fixed-dose combination therapy for the prevention of cardiovascular disease publication-title: Cochrane Database Syst Rev – volume: 6 start-page: 270 year: 2013 end-page: 277 ident: bib31 article-title: Trends in vascular risk factor treatment and control in US stroke survivors: the National Health and Nutrition Examination Surveys (1999-2010) publication-title: Circ Cardiovasc Qual Outcomes – volume: 7 start-page: e41297 year: 2012 ident: bib28 article-title: Randomized polypill crossover trial in people aged 50 and over publication-title: PLoS One – volume: 6 start-page: 261 year: 2010 end-page: 271 ident: bib27 article-title: Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial publication-title: Vasc Health Risk Manag – year: 2017 ident: bib50 article-title: Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review publication-title: Lancet – volume: 22 start-page: 1609 year: 2015 end-page: 1617 ident: bib41 article-title: Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial publication-title: Eur J Prev Cardiol – volume: 70 start-page: 42 year: 2016 end-page: 49 ident: bib54 article-title: Usefulness of a cardiovascular polypill in the treatment of secondary prevention patients in Spain: a cost-effectiveness study publication-title: Rev Esp Cardiol (Engl Ed) – volume: 164 start-page: 836 year: 2016 end-page: 845 ident: bib44 article-title: Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement publication-title: Ann Intern Med – volume: 201 start-page: 671 year: 2014 end-page: 673 ident: bib55 article-title: An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial publication-title: Med J Aust – volume: 120 start-page: 713 year: 2007 end-page: 719 ident: bib5 article-title: Fixed-dose combinations improve medication compliance: a meta-analysis publication-title: Am J Med – reference: (accessed Feb 13, 2017). – volume: 8 start-page: 301 year: 2015 end-page: 308 ident: bib58 article-title: Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial publication-title: Circ Cardiovasc Qual Outcomes – volume: 5 start-page: e007111 year: 2015 ident: bib53 article-title: Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK publication-title: BMJ – volume: 35 start-page: 353 year: 2014 end-page: 364 ident: bib9 article-title: Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges publication-title: Eur Heart J – volume: 63 start-page: 539 year: 2014 end-page: 546 ident: bib32 article-title: Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry) publication-title: J Am Coll Cardiol – volume: 336 start-page: 924 year: 2008 end-page: 926 ident: bib35 article-title: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations publication-title: BMJ – volume: 11 start-page: 129 year: 2016 ident: bib34 article-title: An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial publication-title: Implement Sci – volume: 23 start-page: 1065 year: 2016 end-page: 1076 ident: bib7 article-title: Interventions to improve medication adherence in coronary disease patients: a systematic review and meta-analysis of randomised controlled trials publication-title: Eur J Prev Cardiol – year: 2002 ident: bib1 publication-title: Secondary prevention of noncommunicable diseases in low- and middle-income countries through community-based and health service interventions – volume: 129 start-page: S49 year: 2013 end-page: S73 ident: bib37 article-title: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines publication-title: Circulation – volume: 6 start-page: e19857 year: 2011 ident: bib24 article-title: An international randomised placebo-controlled trial of a four-component combination pill (‘polypill’) in people with raised cardiovascular risk publication-title: PLoS One – volume: 22 start-page: 920 year: 2015 end-page: 930 ident: bib18 article-title: A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk publication-title: Eur J Prev Cardiol – volume: 10 start-page: 2599 year: 2016 end-page: 2609 ident: bib23 article-title: Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) publication-title: Drug Des Devel Ther – volume: 4 year: 2014 ident: bib12 article-title: Fixed-dose combination therapy for the prevention of cardiovascular disease publication-title: Cochrane Database Syst Rev – volume: 102 start-page: 509 year: 2009 end-page: 512 ident: bib46 article-title: The polypill story from a ringside seat publication-title: J R Soc Med – volume: 49 start-page: 528 year: 2015 end-page: 539 ident: bib57 article-title: Patient preferences for a polypill for the prevention of cardiovascular diseases publication-title: Ann Pharmacother – volume: 11 start-page: 22 year: 2009 end-page: 30 ident: bib21 article-title: The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study publication-title: J Clin Hypertens – volume: 6 start-page: 436 year: 2013 end-page: 443 ident: bib36 article-title: Optimal in-hospital and discharge medical therapy in acute coronary syndromes in Kerala: results from the Kerala acute coronary syndrome registry publication-title: Circ Cardiovasc Qual Outcomes – volume: 63 start-page: 1368 year: 2014 end-page: 1370 ident: bib8 article-title: Polypills: essential medicines for cardiovascular disease secondary prevention? publication-title: J Am Coll Cardiol – volume: 27 start-page: 821 year: 2011 end-page: 833 ident: bib15 article-title: Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial publication-title: Curr Med Res Opin – volume: 5 start-page: 463 year: 2012 end-page: 471 ident: bib19 article-title: Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) Investigators publication-title: Circ Cardiovasc Qual Outcomes – volume: 23 start-page: 1537 year: 2016 end-page: 1545 ident: bib52 article-title: Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: findings from a pragmatic randomised controlled trial publication-title: Eur J Prev Cardiol – volume: 12 start-page: e1001862 year: 2015 ident: bib6 article-title: The polypill: from promise to pragmatism publication-title: PLoS Med – volume: 389 start-page: 964 year: 2017 end-page: 972 ident: bib13 article-title: Putting polypills into practice: challenges and lessons learned publication-title: Lancet – year: 2015 ident: bib4 publication-title: 19th WHO model list of essential medicines – volume: 310 start-page: 918 year: 2013 end-page: 929 ident: bib16 article-title: Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial publication-title: JAMA – volume: 378 start-page: 1231 year: 2011 end-page: 1243 ident: bib29 article-title: Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey publication-title: Lancet – volume: 4 start-page: e001709 year: 2015 ident: bib30 article-title: Trends in myocardial infarction secondary prevention: the National Health and Nutrition Examination Surveys (NHANES), 1999–2012 publication-title: J Am Heart Assoc – volume: 100 start-page: ii1 year: 2014 end-page: ii67 ident: bib38 article-title: Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3) publication-title: Heart – reference: . Heart Outcomes and Prevention Evaluation. – volume: 384 start-page: 591 year: 2014 end-page: 598 ident: bib40 article-title: Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data publication-title: Lancet – volume: 33 start-page: 347 year: 2015 end-page: 352 ident: bib56 article-title: The effect of a cardiovascular polypill strategy on pill burden publication-title: Cardiovasc Ther – volume: 6 start-page: 208 year: 2013 end-page: 216 ident: bib33 article-title: The UK National Health Service: delivering equitable treatment across the spectrum of coronary disease publication-title: Circ Cardiovasc Qual Outcomes – volume: 348 start-page: g3318 year: 2014 ident: bib17 article-title: Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care publication-title: BMJ – volume: 21 start-page: 425 year: 2014 end-page: 433 ident: bib49 article-title: The evening versus morning polypill utilization study: the TEMPUS rationale and design publication-title: Eur J Prev Cardiol – volume: 64 start-page: 1220 year: 2010 end-page: 1227 ident: bib22 article-title: A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors publication-title: Int J Clin Prac – year: 2016 ident: bib43 article-title: Estimating longitudinal risks and benefits from cardiovascular preventive therapies among Medicare patients: the Million Hearts Longitudinal ASCVD risk assessment tool: a special report from the American Heart Association and American College of Cardiology publication-title: Circulation – volume: 12 start-page: 3 year: 2011 ident: bib25 article-title: A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization publication-title: Trials – volume: 329 start-page: 1447 year: 2004 end-page: 1450 ident: bib45 article-title: The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75% publication-title: BMJ – year: 2013 ident: bib2 publication-title: Global action plan for the prevention and control of noncommunicable diseases 2013–2020 – year: 2016 ident: bib3 publication-title: HEARTS technical package for cardiovascular disease management in primary health care – volume: 326 start-page: 1419 year: 2003 ident: bib14 article-title: A strategy to reduce cardiovascular disease by more than 80% publication-title: BMJ – year: 2017 ident: bib11 article-title: Cardiovascular polypill: current and evolving landscape for primary and secondary prevention – volume: 70 start-page: 42 year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib54 article-title: Usefulness of a cardiovascular polypill in the treatment of secondary prevention patients in Spain: a cost-effectiveness study publication-title: Rev Esp Cardiol (Engl Ed) doi: 10.1016/j.recesp.2016.05.011 – volume: 8 start-page: 301 year: 2015 ident: 10.1016/S0140-6736(17)30553-6_bib58 article-title: Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial publication-title: Circ Cardiovasc Qual Outcomes doi: 10.1161/CIRCOUTCOMES.115.001483 – volume: 201 start-page: 671 year: 2014 ident: 10.1016/S0140-6736(17)30553-6_bib55 article-title: An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial publication-title: Med J Aust doi: 10.5694/mja14.00266 – volume: 310 start-page: 918 year: 2013 ident: 10.1016/S0140-6736(17)30553-6_bib16 article-title: Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2013.277064 – volume: 1 start-page: 341 year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib42 article-title: Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2016.0218 – volume: 4 year: 2014 ident: 10.1016/S0140-6736(17)30553-6_bib12 article-title: Fixed-dose combination therapy for the prevention of cardiovascular disease publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD009868.pub2 – volume: 374 start-page: 2009 year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib39 article-title: Blood-pressure lowering in intermediate-risk persons without cardiovascular disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1600175 – volume: 63 start-page: 1368 year: 2014 ident: 10.1016/S0140-6736(17)30553-6_bib8 article-title: Polypills: essential medicines for cardiovascular disease secondary prevention? publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2013.08.1665 – volume: 27 start-page: 821 year: 2011 ident: 10.1016/S0140-6736(17)30553-6_bib15 article-title: Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.555754 – volume: 21 start-page: 425 year: 2014 ident: 10.1016/S0140-6736(17)30553-6_bib49 article-title: The evening versus morning polypill utilization study: the TEMPUS rationale and design publication-title: Eur J Prev Cardiol doi: 10.1177/2047487313476961 – volume: 12 start-page: 3 year: 2011 ident: 10.1016/S0140-6736(17)30553-6_bib25 article-title: A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization publication-title: Trials doi: 10.1186/1745-6215-12-3 – volume: 23 start-page: 1065 year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib7 article-title: Interventions to improve medication adherence in coronary disease patients: a systematic review and meta-analysis of randomised controlled trials publication-title: Eur J Prev Cardiol doi: 10.1177/2047487316638501 – volume: 6 start-page: 436 year: 2013 ident: 10.1016/S0140-6736(17)30553-6_bib36 article-title: Optimal in-hospital and discharge medical therapy in acute coronary syndromes in Kerala: results from the Kerala acute coronary syndrome registry publication-title: Circ Cardiovasc Qual Outcomes doi: 10.1161/CIRCOUTCOMES.113.000189 – year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib43 article-title: Estimating longitudinal risks and benefits from cardiovascular preventive therapies among Medicare patients: the Million Hearts Longitudinal ASCVD risk assessment tool: a special report from the American Heart Association and American College of Cardiology publication-title: Circulation doi: 10.1161/CIR.0000000000000467 – volume: 205 start-page: 147 year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib51 article-title: Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2015.12.015 – volume: 100 start-page: ii1 year: 2014 ident: 10.1016/S0140-6736(17)30553-6_bib38 article-title: Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3) publication-title: Heart doi: 10.1136/heartjnl-2014-305693 – volume: 326 start-page: 1419 year: 2003 ident: 10.1016/S0140-6736(17)30553-6_bib14 article-title: A strategy to reduce cardiovascular disease by more than 80% publication-title: BMJ doi: 10.1136/bmj.326.7404.1419 – volume: 11 start-page: 22 year: 2009 ident: 10.1016/S0140-6736(17)30553-6_bib21 article-title: The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study publication-title: J Clin Hypertens doi: 10.1111/j.1751-7176.2008.00058.x – volume: 348 start-page: g3318 year: 2014 ident: 10.1016/S0140-6736(17)30553-6_bib17 article-title: Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care publication-title: BMJ doi: 10.1136/bmj.g3318 – volume: 23 start-page: 1537 year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib52 article-title: Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: findings from a pragmatic randomised controlled trial publication-title: Eur J Prev Cardiol doi: 10.1177/2047487316637196 – volume: 384 start-page: 591 year: 2014 ident: 10.1016/S0140-6736(17)30553-6_bib40 article-title: Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data publication-title: Lancet doi: 10.1016/S0140-6736(14)62070-5 – volume: 12 start-page: e1001862 year: 2015 ident: 10.1016/S0140-6736(17)30553-6_bib6 article-title: The polypill: from promise to pragmatism publication-title: PLoS Med doi: 10.1371/journal.pmed.1001862 – volume: 63 start-page: 539 year: 2014 ident: 10.1016/S0140-6736(17)30553-6_bib32 article-title: Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry) publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2013.09.053 – volume: 378 start-page: 1231 year: 2011 ident: 10.1016/S0140-6736(17)30553-6_bib29 article-title: Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey publication-title: Lancet doi: 10.1016/S0140-6736(11)61215-4 – volume: 389 start-page: 964 year: 2017 ident: 10.1016/S0140-6736(17)30553-6_bib13 article-title: Putting polypills into practice: challenges and lessons learned publication-title: Lancet doi: 10.1016/S0140-6736(17)30558-5 – volume: 336 start-page: 924 year: 2008 ident: 10.1016/S0140-6736(17)30553-6_bib35 article-title: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations publication-title: BMJ doi: 10.1136/bmj.39489.470347.AD – volume: 4 start-page: e001709 year: 2015 ident: 10.1016/S0140-6736(17)30553-6_bib30 article-title: Trends in myocardial infarction secondary prevention: the National Health and Nutrition Examination Surveys (NHANES), 1999–2012 publication-title: J Am Heart Assoc doi: 10.1161/JAHA.114.001709 – volume: 11 start-page: 129 year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib34 article-title: An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial publication-title: Implement Sci doi: 10.1186/s13012-016-0488-1 – volume: 164 start-page: 836 year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib44 article-title: Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement publication-title: Ann Intern Med doi: 10.7326/M16-0577 – volume: 35 start-page: 353 year: 2014 ident: 10.1016/S0140-6736(17)30553-6_bib9 article-title: Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges publication-title: Eur Heart J doi: 10.1093/eurheartj/eht407 – volume: 64 start-page: 2071 year: 2014 ident: 10.1016/S0140-6736(17)30553-6_bib20 article-title: A polypill strategy to improve adherence: results from the FOCUS project publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2014.08.021 – volume: 6 start-page: 270 year: 2013 ident: 10.1016/S0140-6736(17)30553-6_bib31 article-title: Trends in vascular risk factor treatment and control in US stroke survivors: the National Health and Nutrition Examination Surveys (1999-2010) publication-title: Circ Cardiovasc Qual Outcomes doi: 10.1161/CIRCOUTCOMES.113.000112 – volume: 10 start-page: 2599 year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib23 publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S112873 – volume: 5 start-page: e007111 year: 2015 ident: 10.1016/S0140-6736(17)30553-6_bib53 article-title: Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK publication-title: BMJ doi: 10.1136/bmjopen-2014-007111 – year: 2013 ident: 10.1016/S0140-6736(17)30553-6_bib2 – volume: 49 start-page: 528 year: 2015 ident: 10.1016/S0140-6736(17)30553-6_bib57 article-title: Patient preferences for a polypill for the prevention of cardiovascular diseases publication-title: Ann Pharmacother doi: 10.1177/1060028015570468 – volume: 102 start-page: 509 year: 2009 ident: 10.1016/S0140-6736(17)30553-6_bib46 article-title: The polypill story from a ringside seat publication-title: J R Soc Med doi: 10.1258/jrsm.2009.090293 – volume: 373 start-page: 1341 year: 2009 ident: 10.1016/S0140-6736(17)30553-6_bib26 article-title: Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(09)60611-5 – volume: 22 start-page: 1609 year: 2015 ident: 10.1016/S0140-6736(17)30553-6_bib41 article-title: Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial publication-title: Eur J Prev Cardiol doi: 10.1177/2047487314550803 – volume: 6 start-page: 261 year: 2010 ident: 10.1016/S0140-6736(17)30553-6_bib27 article-title: Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial publication-title: Vasc Health Risk Manag doi: 10.2147/VHRM.S7710 – volume: 6 start-page: e19857 year: 2011 ident: 10.1016/S0140-6736(17)30553-6_bib24 article-title: An international randomised placebo-controlled trial of a four-component combination pill (‘polypill’) in people with raised cardiovascular risk publication-title: PLoS One doi: 10.1371/journal.pone.0019857 – volume: 329 start-page: 1447 year: 2004 ident: 10.1016/S0140-6736(17)30553-6_bib45 article-title: The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75% publication-title: BMJ doi: 10.1136/bmj.329.7480.1447 – ident: 10.1016/S0140-6736(17)30553-6_bib47 – year: 2015 ident: 10.1016/S0140-6736(17)30553-6_bib4 – volume: 6 start-page: 208 year: 2013 ident: 10.1016/S0140-6736(17)30553-6_bib33 article-title: The UK National Health Service: delivering equitable treatment across the spectrum of coronary disease publication-title: Circ Cardiovasc Qual Outcomes doi: 10.1161/CIRCOUTCOMES.111.000058 – year: 2002 ident: 10.1016/S0140-6736(17)30553-6_bib1 – volume: 129 start-page: S49 issue: suppl 2 year: 2013 ident: 10.1016/S0140-6736(17)30553-6_bib37 article-title: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines publication-title: Circulation – volume: 33 start-page: 347 year: 2015 ident: 10.1016/S0140-6736(17)30553-6_bib56 article-title: The effect of a cardiovascular polypill strategy on pill burden publication-title: Cardiovasc Ther doi: 10.1111/1755-5922.12151 – volume: 22 start-page: 920 year: 2015 ident: 10.1016/S0140-6736(17)30553-6_bib18 article-title: A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk publication-title: Eur J Prev Cardiol doi: 10.1177/2047487314530382 – year: 2017 ident: 10.1016/S0140-6736(17)30553-6_bib50 article-title: Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review publication-title: Lancet doi: 10.1016/S0140-6736(17)30260-X – year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib3 – volume: 120 start-page: 713 year: 2007 ident: 10.1016/S0140-6736(17)30553-6_bib5 article-title: Fixed-dose combinations improve medication compliance: a meta-analysis publication-title: Am J Med doi: 10.1016/j.amjmed.2006.08.033 – year: 2017 ident: 10.1016/S0140-6736(17)30553-6_bib48 article-title: Fixed-dose combination therapy for the prevention of cardiovascular disease publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD009868.pub3 – volume: 14 start-page: 242 year: 2016 ident: 10.1016/S0140-6736(17)30553-6_bib10 article-title: Could patents interfere with the development of a cardiovascular polypill? publication-title: J Transl Med doi: 10.1186/s12967-016-0997-3 – volume: 7 start-page: e41297 year: 2012 ident: 10.1016/S0140-6736(17)30553-6_bib28 article-title: Randomized polypill crossover trial in people aged 50 and over publication-title: PLoS One doi: 10.1371/journal.pone.0041297 – volume: 5 start-page: 463 year: 2012 ident: 10.1016/S0140-6736(17)30553-6_bib19 article-title: Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) Investigators publication-title: Circ Cardiovasc Qual Outcomes doi: 10.1161/CIRCOUTCOMES.111.963637 – volume: 64 start-page: 1220 year: 2010 ident: 10.1016/S0140-6736(17)30553-6_bib22 article-title: A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors publication-title: Int J Clin Prac doi: 10.1111/j.1742-1241.2010.02412.x – reference: 28290999 - Lancet. 2017 Mar 11;389(10073):984
SSID	ssj0004605
Score	2.514733
SecondaryResourceType	review_article
Snippet	Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose... Summary Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	1055
SubjectTerms	Atherosclerosis Cardiovascular disease Cardiovascular diseases Disease prevention Drug dosages Drug therapy Health risk assessment Heterogeneity Internal Medicine Lipids Malaria Pharmaceutical industry Prevention Purchasing contracts Risk assessment Risk factors Studies Tuberculosis Vector-borne diseases
Title	Uses of polypills for cardiovascular disease and evidence to date
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0140673617305536 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673617305536 https://dx.doi.org/10.1016/S0140-6736(17)30553-6 https://www.ncbi.nlm.nih.gov/pubmed/28290995 https://www.proquest.com/docview/1876470024 https://www.proquest.com/docview/1877527663
Volume	389
WOSCitedRecordID	wos000396345200027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database (ProQuest) customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library (ProQuest) customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NaxQxFA_ainjxu3a1lgge9BCbZJJJ5iS1tHjZdamt7C1k8gGFZWbb2Qr-9yaZzBRhawUvD-bjNxmSl7yXvC8A3ktcxjz7FlFdc8SMd0gLLxA2wmKLayedTsUmxGwmF4tqng_cuuxWOayJaaG2rYln5AckTFsmokj5vLpEsWpUtK7mEhr3wTaJsjvwszj9sSkuMrm430TwHHwfb34g4mNMe1Wg8jbZdJvumWTQyZP__fun4HHWPuFhzy7PwD3XPAcPp9m-_gIcnneug62Hq3b5a3WxXHYwKLXQ_OG0CrNRB-rGQperksJ1C-PhwUtwfnJ8dvQV5SILyHBM1ygGpjpeE0_DoFkhK-OZFVrUuJSOBo3IcsawN7rWBTHSM-7LsKcsNaFWl14XO2CraRu3CyBjXGAf9lNh08KkdbLwReGkMZX2vKjkBLChe5XJGchjIYyl2uBqRoRKo6LKCfg0wlZ9Co67AOUwdmqILw0rogpC4i6g2AR0XZ7XnSKqowr36AgmIkEDUo7IrLr0Ksm_NLo3sIy6aWfklwl4Nz4OMz-ac3Tj2uv0juBUBJVxAl71bDn2T7KPVxV__fePvwGPaFRTon8i2QNb66tr9xY8MD_XF93VfppMkS5EojJQeUT2wfaX49n8NFxNcU_PIqXTRL8lOo9UzH8DfcEopw
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoBLeZdtCxgJJDiYxo4TO4cKVUDVqu0KiVbam3H8kCqtkm2zBfVP8RuxnUeFtKVceuCa5HMSe2Y843kBvBFJHursG0xVmWGmncWKO44TzU1iktIKq2KzCT4ei8mk-LoEv_pcmBBW2cvEKKhNrcMZ-SbxbMt42FI-zk5x6BoVvKt9C42WLPbtxU9vsjVbe5_9-r6ldOfL0add3HUVwDpL6ByHTEyblcRR_5WGi0I7ZrjiZZILS70KYDLGEqdVqVKihWOZy70RlStCjcqdSv24t-C2l-M8hJDxCV-UhxlD6i8zhja_DRffEf4-lNlKcX7VXniVrhv3vJ0H_9tsPYSVTrtG2y07PIIlWz2Gu4dd_MAT2D5ubINqh2b19GJ2Mp02yCvtSP8RlIs6pxVSlUG267qK5jUKhyNP4fhGfuAZLFd1ZZ8DYizjifP2ojfKmDBWpC5NrdC6UC5LCzEC1i-n1F2F9dDoYyoXhNIRLiMVyHwEHwbYrC0xch0g72lF9vmzXuJLvwleB-SLgLbp5FYjiWyoTFp0ABMeoR4pBmSnmrUq17-8dKMnUXn5noE-R_B6uO0lW3BXqcrW5_EZnlHuVeIRrLZsMMxP9P8XRbb298Ffwb3do8MDebA33l-H-zSoZCEWk2zA8vzs3L6AO_rH_KQ5exkZGcH3m-aF35x8e9I
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgiouvFuWFjASSHAI6zh27BwQqigrqtJVJVqpN-P4IVVaJUuzBfWv8etqO48KaUu59MA1yeck9oxnxv7GA_Ba4Dycs28SokqWUO1sorjjCdbcYINLK6yKxSb4dCqOj4uDFfjd58IEWmU_J8aJ2tQ6rJGPU6-2lAeTMnYdLeJgZ_Jx_iMJFaTCTmtfTqMVkT17_suHb82H3R0_1m8ImXw-_PQl6SoMJJphskhCVqZlZeqI_2LDRaEdNVzxEufCEu8OGEYpdlqVKku1cJS53AdUuUqJUblTmW_3FtzmlJFAJ9vHh8tyMiO9_jJ7aPxtuPg25e_CkVtZkl9lF6_ye6P9m9z_n3vuAdzrvG603arJQ1ix1SNY2-94BY9h-6ixDaodmtez8_nJbNYg78wj_QdZF3WbWUhVBtmuGita1CgsmjyBoxv5gXVYrerKPgVEKePY-TjSB2tUGCsyl2VWaF0ox7JCjID2Qyt1d_J6KAAyk0sodimXUSJkPoL3A2zeHj1yHSDv5Ub2ebXeEkhvHK8D8mVA23TzWSNT2RCJW3QApzxCPVIMyM5la12xf3npVi-u8vI9g6yO4NVw2894YRtLVbY-i89wRrh3lUew0arE0D-RF1AU7NnfG38Ja14F5Nfd6d4m3CXBUwsUzXQLVhenZ_Y53NE_FyfN6Yuo0wi-37QqXADd8ISi
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Uses+of+polypills+for+cardiovascular+disease+and+evidence+to+date&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Huffman%2C+Mark+D&rft.au=Xavier%2C+Denis&rft.au=Perel%2C+Pablo&rft.date=2017-03-11&rft.pub=Elsevier+Ltd&rft.issn=0140-6736&rft.eissn=1474-547X&rft.volume=389&rft.issue=10073&rft.spage=1055&rft.epage=1065&rft_id=info:doi/10.1016%2FS0140-6736%2817%2930553-6&rft.externalDocID=S0140673617305536
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673617X00111%2Fcov150h.gif